Brief: Humanigen Reports Positive Data With Lenzilumab In The Zuma-19 CAR-T Phase 1B Study In DLBCL And Plans To Initiate Potential Registrational Study

Humanigen

19/04/2021 12:11

April 19 (Reuters) - Humanigen Inc  HGEN.O :
    * HUMANIGEN REPORTS POSITIVE DATA WITH LENZILUMAB IN THE
ZUMA-19
CAR-T PHASE 1B STUDY IN DLBCL AND PLANS TO INITIATE A POTENTIAL
REGISTRATIONAL STUDY
    * HUMANIGEN INC - LENZILUMAB REDUCED IL-6, CRP, FERRITIN,
MCP-1,
IL-8, AND IP-10 (CXCL-10) AMONG OTHERS
    * HUMANIGEN - PLANS TO CONDUCT PHASE 2 STUDY WITH LENZILUMAB
COMBINED WITH ALL COMMERCIALLY AVAILABLE CD19 CAR-T THERAPIES IN
DLBCL
    * HUMANIGEN INC - TERMINATED ZUMA-19 CLINICAL COLLABORATION
AGREEMENT WITH KITE, A GILEAD COMPANY
    * HUMANIGEN INC - AT RECOMMENDED PHASE 2 DOSE, LENZILUMAB IN
COMBINATION WITH CAR-T, DEMONSTRATED A 100% OBJECTIVE RESPONSE
RATE

Source text for Eikon:  ID:nBwc0xK8va 
Further company coverage:  HGEN.O 

 ((Reuters.Briefs@thomsonreuters.com;))